EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 294 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... April 12, 2024 Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a...
